|Bid||62.31 x 1100|
|Ask||62.32 x 1000|
|Day's Range||62.24 - 62.94|
|52 Week Range||52.83 - 66.41|
|PE Ratio (TTM)||108.33|
|Earnings Date||Jul 27, 2018|
|Forward Dividend & Yield||1.92 (3.09%)|
|1y Target Est||69.44|
Yahoo Finance’s Seana Smith and Jared Blikre break down the minutes from the Fed's June meeting and the other big headlines moving stocks in midday trading Thursday.
Advaxis (ADXS), in collaboration with Merck & Co. (MRK), is conducting a Phase 1 Part 2 trial to evaluate the safety and efficacy of ADXS-PSA as a monotherapy and in combination with Merck’s Keytruda in patients with previously treated metastatic, castration-resistant prostate cancer. In the trial, 13 patients were evaluated on monotherapy and 37 patients were evaluated on combination therapy. The safety profile was found to be consistent with prior clinical studies that used Lm Technology.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. MRK credit default swap spreads are within the middle of their range for the last three years.
Pfizer, the worlds second largest pharmaceutical company, announced on Wednesday, July 11th, plans to split into three separate businesses in a major restructuring move. The Innovative Medicines division will bring in most of Pfizer’s revenue. In a press release, the company said that the growth potential for that business is strongest in part because of the aging population which will increase the demand for new medicines.
and a top European meat processor are backing a startup producing beef from cattle cells, ramping up a race to transform the global meat industry with cell-culture technology. fuels a continuing effort to fulfill growing global demand for meat via a process that developers say requires a fraction of the resources used in traditional livestock and poultry production.
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
The index enjoyed a strong week of gains, boosted by expectations of a strong second quarter earnings season.
Moody's Investors Service, ("Moody's") has today affirmed the Baa1 long-term issuer rating of Merck KGaA (Merck). Moody's has also affirmed the ratings of Merck's short term issuer, senior unsecured Medium Term Note program and junior subordinated ratings at P-2, (P)Baa1 and Baa3 respectively.
The FDA grants a priority review to Merck's (MRK) label expansion filing for its key cancer drug Keytruda regarding the first-line treatment of advanced HCC.
Merck & Co. Inc. ( MRK) shares have dramatically outperformed the S&P 500 this year, rising 10%. Those gains may be just the start. Analysts are looking for the stock to rise by nearly 12% higher to about $69. The analysts aren't the only ones all bulled up on the pharmaceutical company.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $375 million.
Application Based on Monotherapy Data from Phase 2 KEYNOTE-224 Trial
President Donald Trump criticized pharmaceutical giant Pfizer Inc. (PFE) in a Monday tweet for recently increasing the prices of many of its prescription drugs. In the tweet, which referred to Pfizer and unspecified "others," Trump said that companies were "merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere. The presidential tweet follows a Financial Times report that Pfizer raised list prices for 100 products in early July, weeks after Trump promised large price reductions, and marking the second such increase this year for Pfizer.
One of the most often used arguments in favor of owning Johnson & Johnson (NYSE:JNJ) is its diversity. Diversification in and of itself doesn’t inherently make a company worth buying into, however. J&J has maintained its stature as one of the most recognizable names (if not the most recognizable name) in the healthcare arena.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $4.54 billion.
Jim Cramer rattles off his take on callers' favorite stocks, including a drugmaker that's topping its competition.
Biogen (NASDAQ:BIIB) is the hot stock of the moment thanks to success in a trial of an Alzheimer’s drug. Progress on Alzheimers makes Biogen stock worth at least a look, right? Both follow the so-called “amyloid hypothesis,” the idea that reducing amyloid plaques using monoclonal antibodies can reverse the disease.
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
To receive further updates on this Novocure Ltd (NASDAQ:NVCR) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.
AstraZeneca (AZN.L) suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Soriot and his team are increasingly confident that while AstraZeneca may have lost one part of the battle for cancer market dominance, it can still win elsewhere by targeting tumours before they have spread around the body. The idea that immunotherapy may actually work best in less sick patients is logical, since the immune system's natural role is to destroy nascent tumours.
In July, the FDA accepted for review Merck & Co.’s (MRK) sBLA (supplemental Biologics License Application) for Keytruda in combination with carboplatin-paclitaxel or nab-paclitaxel in the first-line setting for the treatment of individuals with metastatic squamous non-small cell lung cancer (or sNSCLC), irrespective of PD-L1 expression.
Pfizer Inc. ( PFE) shares have dramatically underperformed during the past three years, rising 9.4% compared to the S&P 500's rise of nearly 31%. Options traders are also betting the stock will gain in the next few months. Pfizer has not only underperformed the broader stock market, but its valuation is among the cheapest of some of the other big pharmaceuticals.
Pfizer (NYSE:PFE) is a pharma/biotech dinosaur. This stock is a survivor of decades of stock market turmoils and corrections. It currently sits on a potential long-term technical breakout point on the monthly chart.